SYDNEY, April 9 (Reuters) - Australia's federal government faces a tense meeting with state and territory leaders on Friday after an abrupt change to the country's vaccination program triggered by a recommendation that people under 50 take Pfizer (NYSE:PFE)'s PFE.N COVID-19 vaccine rather than AstraZeneca (NASDAQ:AZN)'s AZN.L shot.
Late the previous day, Prime Minister Scott Morrison said the policy shift, which was based on possible links between AstraZeneca's shot and rare cases of blood clots, would delay Australia's inoculation plans which were already behind schedule due to a supply shortage. had ordered 20 million doses of the Pfizer vaccine, enough for 10 million of its population of nearly 26 million, but had banked on the AstraZeneca vaccine for the majority of shots with biopharma CSL Ltd CSL.AX contracted to make 50 million doses domestically.
On Thursday the Australian authorities changed their recommendation after European regulators reiterated the possibility of links between AstraZeneca's shot and reports of very rare cases of blood clots. Plans to have the entire population vaccinated by the end of October would be pushed back as a result, Morrison said.
"This does change the game for Australia and not in a good way," the opposition Labor party's deputy senate leader Kristina Keneally told the Australian Broadcasting Corp on Friday.
"While we are lucky we don't have high rates of community transmission at the moment, we know that can change."
After a hardline response to the coronavirus largely stopped community transmissions, the vaccination rollout has become a hot political topic - and a source of friction between Morrison and state and territory leaders - after the country missed a target of having four million people vaccinated by end-March.
Australia began vaccinations much later than some other nations because of its low number of infections, which stand at just under 29,400, with 909 deaths, since the pandemic began.